Creative Medical Technology Holdings Files Proxy Statement

Ticker: CELZ · Form: DEF 14A · Filed: Jun 5, 2024 · CIK: 1187953

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

Related Tickers: CMED

TL;DR

CMED proxy filed for July 19th meeting - shareholders vote on company direction.

AI Summary

Creative Medical Technology Holdings, Inc. filed its definitive proxy statement on June 5, 2024, for its annual meeting on July 19, 2024. The company, formerly known as Jolley Marketing Inc., is seeking shareholder approval for matters related to its corporate governance and operations. The filing does not disclose specific proposals but indicates a standard proxy process for a publicly traded company.

Why It Matters

This filing is crucial for shareholders as it outlines the proposals and information needed to vote on company matters, directly impacting the company's future direction and governance.

Risk Assessment

Risk Level: medium — Proxy statements can reveal important information about executive compensation, board composition, and shareholder proposals, which may indicate potential shifts in company strategy or governance that could affect stock value.

Key Players & Entities

FAQ

What is the primary purpose of this DEF 14A filing?

The primary purpose of this DEF 14A filing is to provide shareholders with a proxy statement for the upcoming annual meeting, outlining information necessary for them to vote on company matters.

When is the scheduled date for the annual meeting?

The scheduled date for the annual meeting is July 19, 2024.

What was the former name of Creative Medical Technology Holdings, Inc.?

The former name of Creative Medical Technology Holdings, Inc. was JOLLEY MARKETING INC.

On what date was this definitive proxy statement filed?

This definitive proxy statement was filed on June 5, 2024.

What is the SIC code for Creative Medical Technology Holdings, Inc.?

The Standard Industrial Classification (SIC) code for Creative Medical Technology Holdings, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 4,894 words · 20 min read · ~16 pages · Grade level 11.6 · Accepted 2024-06-05 16:05:11

Key Financial Figures

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 11 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 15

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 18 PROPOSAL ONE: ELECTION OF DIRECTORS 19 PROPOSAL TWO: APPROVAL OF AN AMENDMENT TO OUR ARTICLES OF INCORPORATION INCREASING THE NUMBER OF OUR AUTHORIZED SHARES OF COMMON STOCK FROM 5,000,000 SHARES TO 25,000,000 SHARES 20 PROPOSAL THREE: ADVISORY VOTE ON EXECUTIVE COMPENSATION 21 PROPOSAL FOUR: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS 22 AUDIT COMMITTEE REPORT 23 OTHER MATTERS 23 PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held at 9:00 a.m. Pacific Standard Time on July 19, 2024 This proxy statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our Board of Directors (the "Board" or "Board of Directors") for use at the 2024 annual meeting of stockholders of Creative Medical Technology Holdings, Inc., a Nevada corporation, and any postponements, adjournments or continuations thereof (the "Annual Meeting"). The Annual Meeting will be held on July 19, 2024 at 9:00 a.m. Pacific Standard Time at 440 Stevens Avenue, Suite #200, Solana Beach, CA 92075. References in this Proxy Statement to "we," "us," "our," the "Company" or "Creative Medical Technology Holdings" refer to Creative Medical Technology Holdings, Inc. The Notice of Internet Availability of Proxy Materials (the "Notice") containing instructions on how to access this Proxy Statement and our Annual Report is first being mailed on or about June 7, 2024 to all stockholders entitled to vote at the Annual Meeting. THE INFORMATION PROVIDED IN THE "QUESTION AND ANSWER" FORMAT BELOW IS FOR YOUR CONVENIENCE ONLY AND IS MERELY A SUMMARY OF THE INFORMATION CONTAINED IN THIS PROXY STATEMENT. YOU SHOULD READ THIS ENTIRE PROXY STATEMENT CAREFULLY. 1 Table of Contents QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND OUR ANNUAL MEETING Q: What is included in the proxy materials? A: The proxy materials include this Proxy Stat

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing